Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 14, Issue 3, Pages 169-175

Serum Mucin Antigen (CASA) as a Marker of Amiodarone-Induced Pulmonary Toxicity

Peter L. Devine,1 Wendy J. Siebert,2 Sharon L. Morton,3 Betty Scells,4 Rachel J. Quin,1 William F. Heddle,3 Paul V. Zimmerman,4 and Peter J. Donohoe5

1Department of Obstetrics & Gynaecology, University of Queensland, Brisbane, Australia
2Department of Pharmacy, Flinders Medical Centre, Adelaide, Australia
3Department of Medicine, Flinders Medical Centre, Adelaide, Australia
4Department of Thoracic Medicine, Prince Charles Hospital, Chermside, Queensland, Australia
5Department of Immunology, Allergy and Arthritis, Flinders Medical Centre, Adelaide, Australia

Received 9 December 1999; Accepted 9 December 1999

Copyright © 1998 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Amiodarone is used to treat life-threatening cardiac arrhythmias. Amiodarone-induced pulmonary toxicity (APT) can be difficult to diagnose. APT may result in increased mucus production and mucin expression. Thus, serum mucin-1 was evaluated as a marker for amiodarone-induced pulmonary toxicity. Concentrations of mucin-1 in peripheral blood were determined using cancer-associated serum antigen (CASA) assay in patients taking amiodarone. Eight of ten patients who developed major amiodarone toxicity had high serum CASA levels. Patients with toxicity had a significantly higher mean rank CASA concentration compared with those without major toxicity. CASA shows potential as a marker for amiodarone-induced toxicity, particularly pulmonary toxicity.